HIV drugs. Lab technician at the Trimeris Biopharmaceutical Company examines a bottle of T-20, the first developed in a class of investigational drugs called fusion inhibitors. T-20 works to block the HIV virus before it enters and takes over a host cell. Based in Durham, North Carolina, Trimeris conducts development-stage research and production of anti-viral drugs.